Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

Celgene: KarMMa-3 Ph3 Randomized bb2121 vs Standard regimen in RRMM (Multiple Myeloma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn more about how about the study drug (bb2121) affects people with relapsed and refractory multiple myeloma compared to standard treatment.
What is the Condition Being Studied?
Relapsed and Refractory Multiple Myeloma

Who Can Participate in the Study?

Adults who have Relapsed/Refractory Multiple Myeloma

Age Group

What is Involved?

If you chose to be in the study you will:
- Have a physical exam
- Take a memory test
- Give blood and urine samples
- Complete questionnaires
- Be randomized (like flipping a coin) to take the study drug bb2121 or the standard treatment
- Get x-rays of body

Study Details

Full Title
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Principal Investigator
Cell Therapy and Hematologic Malignancies Specialist
Protocol Number
IRB: PRO00100712
NCT: NCT03651128
Phase III
Contact the Duke Recruitment Innovation Center